Brain Tumors and Cancer Stem Cells - Highlights from Brain Works 2013
Excerpt from Brain Works 2013, a free community event from Washington University and Barnes-Jewish Hospital. Register for our next brain innovation event at:...
By: Barnes-Jewish Hospital
View post:
Brain Tumors and Cancer Stem Cells - Highlights from Brain Works 2013 - Video
Biotechnology training for stem cell-related jobs265
By: Barbara Poplits
Read this article:
Biotechnology training for stem cell-related jobs265 - Video
Arthritis Treatment...Three Dimensional Scaffolds Help Stem Cells Produce Hyaline Cartilage
http://www.stemcellsarthritistreatment.com The use of 3 D scaffolds to help stem cells build hyaline cartilage for arthritis treatment is the topic of this b...
By: Nathan Wei
Here is the original post:
Arthritis Treatment...Three Dimensional Scaffolds Help Stem Cells Produce Hyaline Cartilage - Video
Pre-Leukemic Stem Cells Discovered by Canada Scientists to Prevent Blood Cancer
Canadian Researchers have Discovered a Pre-Leukemic Stem cell that may be at the Root of Acute Myeloid Leukemia and also be the "bad actor" that Evades Chemo...
By: V6NewsTelugu
More here:
Pre-Leukemic Stem Cells Discovered by Canada Scientists to Prevent Blood Cancer - Video
stem cell research stem cell therapy marrow transplant and lung repair stem cell transplant
Learn more: http://www.ez3dbiz.com/rejuvenessence.html.
By: 3dbizez
See more here:
stem cell research stem cell therapy marrow transplant and lung repair stem cell transplant - Video
adult stem cell therapy blood bone marrow astragalus herb benefits for rheumatoid arthritis
Learn more at: http://www.ez3dbiz.com/rejuvenessence.html.
By: 3dbizez
Read more:
adult stem cell therapy blood bone marrow astragalus herb benefits for rheumatoid arthritis - Video
PUBLIC RELEASE DATE:
16-Feb-2014
Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center
STANFORD, Calif. Researchers at the Stanford University School of Medicine have pinpointed why normal aging is accompanied by a diminished ability to regain strength and mobility after muscle injury: Over time, stem cells within muscle tissues dedicated to repairing damage become less able to generate new muscle fibers and struggle to self-renew.
"In the past, it's been thought that muscle stem cells themselves don't change with age, and that any loss of function is primarily due to external factors in the cells' environment," said Helen Blau, PhD, the Donald and Delia B. Baxter Foundation Professor. "However, when we isolated stem cells from older mice, we found that they exhibit profound changes with age. In fact, two-thirds of the cells are dysfunctional when compared to those from younger mice, and the defect persists even when transplanted into young muscles."
Blau and her colleagues also identified for the first time a process by which the older muscle stem cell populations can be rejuvenated to function like younger cells. "Our findings identify a defect inherent to old muscle stem cells," she said. "Most exciting is that we also discovered a way to overcome the defect. As a result, we have a new therapeutic target that could one day be used to help elderly human patients repair muscle damage."
Blau, a professor of microbiology and immunology and director of Stanford's Baxter Laboratory for Stem Cell Biology, is the senior author of a paper describing the research, which will be published online Feb. 16 in Nature Medicine. Postdoctoral scholar Benjamin Cosgrove, PhD, and former postdoctoral scholar Penney Gilbert, PhD, now an assistant professor at the University of Toronto, are the lead authors.
The researchers found that many muscle stem cells isolated from mice that were 2 years old, equivalent to about 80 years of human life, exhibited elevated levels of activity in a biological cascade called the p38 MAP kinase pathway. This pathway impedes the proliferation of the stem cells and encourages them to instead become non-stem, muscle progenitor cells. As a result, although many of the old stem cells divide in a dish, the resulting colonies are very small and do not contain many stem cells.
Using a drug to block this p38 MAP kinase pathway in old stem cells (while also growing them on a specialized matrix called hydrogel) allowed them to divide rapidly in the laboratory and make a large number of potent new stem cells that can robustly repair muscle damage, Blau said.
"Aging is a stochastic but cumulative process," Cosgrove said. "We've now shown that muscle stem cells progressively lose their stem cell function during aging. This treatment does not turn the clock back on dysfunctional stem cells in the aged population. Rather, it stimulates stem cells from old muscle tissues that are still functional to begin dividing and self-renew."
See the article here:
Researchers rejuvenate stem cell population from elderly mice, enabling muscle recovery
Instead of being shut out of a $40 million stem cell grant awarded to Stanford University, San Diego researchers will be major partners, say the scientists who lead the project.
Joseph Ecker of the Salk Institute and Michael Snyder of Stanford say that under an informal arrangement, they will jointly allocate money granted from the California Institute for Regenerative Medicine for a new center on stem cell genomics. CIRM is responsible for distributing $3 billion in state bond money to turn stem cell research into disease treatments.
Joseph Ecker, a Salk Institute researcher and co-principal investigator of the new center for stem cell genomics created with a $40 million grant from the California Institute for Regenerative Medicine. / Salk Institute
Genomics, the study of the complete set of genes and DNA in an organism, is necessary to help understand how stem cells function. Stem cells contain virtually the same genes as adult cells but differ in which genes are turned on and off. The signals that cause stem cells to differentiate are not well understood.
By analyzing the genomes of stem cells, researchers expect to better understand how stem cells can produce more stem cells, and which genes are involved in directing stem cells down the path to becoming adult cells of interest, such as islet cells that make insulin, bone or retinal cells.
Last months decision had been characterized as a big win for Stanford, because the university had been awarded the grant over competing applications, including one from The Scripps Research Institute and San Diego DNA sequencing giant Illumina.
Ecker and Snyder said that belief is a misunderstanding, because their proposal is a cooperative venture involving extensive participation from San Diego biomedical scientists.
Michael Snyder, a Stanford University researcher and co-principal investigator of the new center for stem cell genomics created with a $40 million grant from the California Institute for Regenerative Medicine. / Stanford University
The leadership issue is confusing, because CIRM requires a single institute to be listed as the lead on funding proposals, even if the institutions are sharing leadership, Ecker said by email. In fact, Mike Snyder and I, by proxy Stanford and Salk, are equal partners. Responsibility for administration of the center will fall equally to Stanford and Salk researchers, as well as strategic steering and decision-making on what projects to pursue.
Besides Salk and Stanford, partners are UC San Diego, the Ludwig Institute for Cancer Research, the J. Craig Venter Institute, The Scripps Research Institute and UC Santa Cruz. The Howard Hughes Medical Institute also plays a role.
Original post:
Salk, Stanford equal partners in stem cell genomics program
Genetic Manipulation in Stem Cells - Rudolf Jaenisch
Source - http://serious-science.org/videos/275 MIT Prof. Rudolf Jaenisch on the problems of developmental biology, isogenic control, and homologous recombination.
By: SeriousScience
View original post here:
Genetic Manipulation in Stem Cells - Rudolf Jaenisch - Video
PUBLIC RELEASE DATE:
13-Feb-2014
Contact: Joseph Caputo joseph_caputo@harvard.edu 617-496-1491 Harvard University
Harvard stem cell scientists have a new theory for how stem cells decide whether to become liver or pancreatic cells during development. A cell's fate, the researchers found, is determined by the nearby presence of prostaglandin E2, a messenger molecule best known for its role in inflammation and pain. The discovery, published in the journal Developmental Cell, could potentially make liver and pancreas cells easier to generate both in the lab and for future cell therapies.
Wolfram Goessling, MD, PhD, and Trista North, PhD, both principal faculty members of the Harvard Stem Cell Institute (HSCI), identified a gradient of prostaglandin E2 in the region of zebrafish embryos where stem cells differentiate into the internal organs. Experiments conducted by postdoctoral fellow Sahar Nissim, MD, PhD, in the Goessling lab showed how liver-or-pancreas-fated stem cells have specific receptors on their membranes to detect the amount of prostaglandin E2 hormone present and coerce the cell into differentiating into a specific organ type.
"Cells that see more prostaglandin become liver and the cells that see less prostaglandin become pancreas," said Goessling, a Harvard Medical School Assistant Professor of Medicine at Brigham and Women's Hospital and Dana-Farber Cancer Institute. "This is the first time that prostaglandin is being reported as a factor that can lead this fate switch and essentially instruct what kind of identity a cell is going to be."
The researchers next collaborated with the laboratory of HSCI Affiliated Faculty member Richard Maas, MD, PhD, Director of the Genetics Division at Brigham and Women's Hospital, to see whether prostaglandin E2 has a similar function in mammals. Richard Sherwood, PhD, a former graduate student of HSCI Co-director Doug Melton, was successfully able to instruct mouse stem cells to become either liver or pancreas cells by exposing them to different amounts of the hormone. Other experiments showed that prostaglandin E2 could also enhance liver growth and regeneration of liver cells.
Goessling and his research partner North, a Harvard Medical School Assistant Professor of Pathology at Beth Israel Deaconess Hospital, first became intrigued by prostaglandin E2 in 2005, as postdoctoral fellows in the lab of HSCI Executive Committee Chair Leonard Zon, MD. It caught their attention during a chemical screen exposing 2,500 known drugs to zebrafish embryos to find any that could amplify blood stem cell populations. Prostaglandin E2 was the most successful hit the first molecule discovered in any system to have such an effectand recently successfully completed Phase 1b clinical trials as a therapeutic to improve cord blood transplants.
"Prostaglandin might be a master regulator of cell growth in different organs," Goessling said. "It's used in cord blood, as we have shown, it works in the liver, and who knows what other organs might be affected by it."
With evidence of how prostaglandin E2 works in the liver, the researchers next want to calibrate how it can be used in the laboratory to instruct induced pluripotent stem cellsmature cells that have been reprogrammed into a stem-like stateto become liver or pancreas cells. The scientists predict that such a protocol could benefit patients who need liver cells for transplantation or who have had organ injury.
Follow this link:
Harvard scientists find cell fate switch that decides liver, or pancreas?
Poway, California (PRWEB) February 13, 2014
The leading Regenerative Veterinary Medicine company, Vet-Stem, Inc., and Americas best-loved pet insurer, Petplan, are working together to bring stem cell therapy and other regenerative cell therapies to pets nationwide. Stem cell therapy by Vet-Stem has been available for pets like dogs and cats for the last decade and covered by Petplan since 2010.
Founded in 2003 by Chris and Natasha Ashton, Petplan was recently named to Forbes magazines annual ranking of Americas Most Promising Companies for the second year in a row, and is rated one of the top pet insurance companies by Consumer Advocate and Canine Journal. Petplan proudly offers life-long coverage for hereditary and chronic conditions as well as alternative treatments, like stem cell therapy, as standard.
Our core value is that pets come first, and that starts with our comprehensive plans. So, were excited to see so many of our policyholders start to take advantage of cutting-edge treatments like Vet-Stem Regenerative Cell Therapy. Our team thrives on being able to provide coverage for the best and most up-to-date treatment modalities for the pets in our Petplan family, so hearing great stories about stem cell therapy from our policyholders is a real boost for us! - Dr. Jules Benson, Vice President of Veterinary Services at Petplan
Current uses of stem cell therapy are treating the pain and inflammation from arthritis and to repair orthopedic injuries. According to veterinarians, greater than 80% of dogs showed an improved quality of life after stem cell therapy. At 90 days post-treatment, more than 33% of dogs discontinued use of non-steroidal anti-inflammatory drugs (NSAIDs) completely, with an additional 28% decreasing their usage.
I started Vet-Stem in order to help horses with career-ending injuries to their tendons and ligaments, but so many more animals have been saved from a life of pain or even from euthanasia. I feel privileged and excited to be a part of this therapy that has changed how veterinary medicine is practiced, as well as contributing to changes in human medicine, - Robert Harman, DVM, CEO, Vet-Stem, Inc.
About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.
Continue reading here:
Vet-Stem, Inc. and Petplan Work Together in the New Year to Bring Regenerative Cell Therapies to Pets
Contact Information
Available for logged-in reporters only
Newswise Researchers at the University of California, San Diego School of Medicine have discovered that a well-known protein has a new function: It acts in a biological circuit to determine whether an immature neural cell remains in a stem-like state or proceeds to become a functional neuron.
The findings, published in the February 13 online issue of Cell Reports, more fully illuminate a fundamental but still poorly understood cellular act and may have significant implications for future development of new therapies for specific neurological disorders, including autism and schizophrenia.
Postdoctoral fellow Chih-Hong Lou, working with principal investigator Miles F. Wilkinson, PhD, professor in the Department of Reproductive Medicine and a member of the UC San Diego Institute for Genomic Medicine, and other colleagues, discovered that this critical biological decision is controlled by UPF1, a protein essential for the nonsense-mediated RNA decay (NMD) pathway.
NMD was previously established to have two broad roles. First, it is a quality control mechanism used by cells to eliminate faulty messenger RNA (mRNA) molecules that help transcribe genetic information into the construction of proteins essential to life. Second, it degrades a specific group of normal mRNAs. The latter function of NMD has been hypothesized to be physiologically important, but until now it had not been clear whether this is the case.
Wilkinson and colleagues discovered that in concert with a special class of RNAs called microRNA, UPF1 acts as a molecular switch to determine when immature (non-functional) neural cells differentiate into non-dividing (functional) neurons. Specifically, UPF1 triggers the decay of a particular mRNA that encodes for a protein in the TGF- signaling pathway that promotes neural differentiation. By degrading that mRNA, the encoded protein fails to be produced and neural differentiation is prevented. Thus, Lou and colleagues identified for the first time a molecular circuit in which NMD acts to drive a normal biological response.
NMD also promotes the decay of mRNAs encoding proliferation inhibitors, which Wilkinson said may explain why NMD stimulates the proliferative state characteristic of stem cells.
There are many potential clinical ramifications for these findings, Wilkinson said. One is that by promoting the stem-like state, NMD may be useful for reprogramming differentiated cells into stem cells more efficiently.
Another implication follows from the finding that NMD is vital to the normal development of the brain in diverse species, including humans. Humans with deficiencies in NMD have intellectual disability and often also have schizophrenia and autism. Therapies to enhance NMD in affected individuals could be useful in restoring the correct balance of stem cells and differentiated neurons and thereby help restore normal brain function.
Follow this link:
Protein Switch Dictates Cellular Fate: Stem Cell or Neuron
Total Recovery Lecture Series: Novel Treatments for Joint, Tendon Ligament Pain, Part 3
Part 3: Regenerative Therapies: Prolotherapy, Platelet Rich Plasma (PRP) and Stem Cell Therapy Dr. David Wang, Harvard trained and Board Certified in Physica...
By: KaplanCenter
Read the rest here:
Total Recovery Lecture Series: Novel Treatments for Joint, Tendon & Ligament Pain, Part 3 - Video
What is Stem Cell Therapy?
According to J. Peter Rubin, MD, Chair of the University of Pittsburgh #39;s Department of Plastic Surgery, stem cells are small cells that live within the tissu...
By: Smart Beauty Guide
See the rest here:
What is Stem Cell Therapy? - Video
Stem Cells therapy - Age Reversal Study - Carmen
http://a1stemcells.com/anti-aging-2 Carmen #39;s testimonial recorded during her 7th injection. Stem cell rejuvenation program is taking place in Mexico If you w...
By: A1 Stem Cells
Originally posted here:
Stem Cells therapy - Age Reversal Study - Carmen - Video
Total Recovery Lecture Series: Novel Treatments for Joint, Tendon Ligament Pain, Part 3
Part 3: Regenerative Therapies: Prolotherapy, Platelet Rich Plasma (PRP) and Stem Cell Therapy Dr. David Wang, Harvard trained and Board Certified in Physica...
By: KaplanCenter
Here is the original post:
Total Recovery Lecture Series: Novel Treatments for Joint, Tendon & Ligament Pain, Part 3 - Video
Advanced Stem Cell Therapy and PRP Treatment
Subscribe to Tv5 News Channel: http://goo.gl/NHJD9 Like us on Facebook: http://www.facebook.com/tv5newschannel Follow us on Twitter: https://twitter.co...
By: TV5 News
See the article here:
Advanced Stem Cell Therapy and PRP Treatment - Video
Actualizacin de Baruc perro tratado con clulas madre, Costa Rica, dog treated with Stem Cells
Para ms informacin sobre los tratamientos con Clulas Madre, favor escribir al correo innovacelulasmadre@gmail.com o llamar al +(506) 88254973 Msica escog...
By: Priscilla Ortiz
Continued here:
Actualizacin de Baruc perro tratado con clulas madre, Costa Rica, dog treated with Stem Cells - Video
Disgraced Korean scientist receives stem cell research patent
A former leading Korean geneticist has received a U.S patent on a controversial stem cell line that sparked a scandal nearly a decade ago. Hwang Woo-suk was ...
By: ARIRANG NEWS
Read the original:
Disgraced Korean scientist receives stem cell research patent - Video
Stem cells and human health
Public lecture by Professor Fiona Watt FRS, Director of the Centre for Stem Cells and Regenerative Medicine at Kings College London. The field of stem cells ...
By: RoyalSociety
View original post here:
Stem cells and human health - Video